NHS Framework Agreement for Branded Medicines - Proprietary Category Tender
Buyer: NHS EnglandSupplier: Abbvie Ltd; Accord-UK Ltd; Alissa Healthcare Research Limited; Aspen Pharmacare UK Limited; Aspire Pharma Ltd; Astellas Pharma Ltd; Aventis Pharma ltd t/a Sanofi; Baxter Healthcare Ltd; Bayer Plc; Besins Healthcare UK LTD; BioCryst Ireland Limited; CELIX PHARMA LTd; CSL BEHRING UK LIMITED; CST Pharma Ltd; Chiesi Limited; Colonis Pharma Ltd; DRUGSRUS LIMITED; Day Lewis Medical Ltd; Dexcel Pharma Ltd; Eisai Ltd; Essential Pharma; Esteve Pharmaceuticals Limited; Ferring Pharmaceuticals Ltd; Flynn Pharma Ltd; G.L. Pharma UK Limited; GLENMARK PHARMACEUTICALS EUROPE LIMITED; Galen; Gedeon Richter UK Ltd; Grunenthal; Infectopharm Ltd; Ipsen Ltd; Janssen-Cilag Ltd; Kyowa Kirin International UK New Co Ltd; Lupin Healthcare (UK) Limited; MERCURY PHARMACEUTICALS LIMITED; Merck Serono; Merz; Morningside Pharmaeuticals; Mylan; NOVARTIS PHARMACEUTICALS UK LIMITED; Napp Pharmaceuticals Ltd; Neon Healthcare; Neuraxpharm UK Ltd; Nordic Pharma Ltd; Norgine Pharmaceuticals Limited; Novo Nordisk; Organon Pharmaceuticals UK Ltd; Orifarm UK; Otsuka Pharmaceuticals UK Limited; PROVEPHARM UK LTD; Pfizer Ltd; Pharmasure Ltd; Pharming Group; ROVI Biotech Limited; Rayner Surgical Group Ltd; Recordati Rare Diseases UK Ltd; Ridge Pharma; SELECTIVE SUPPLIES LIMITED; SERB SA; Sandoz Ltd; Strandhaven Ltd T/A Somex Pharma; Sun Pharma UK Ltd; Synchrony; TILLOMED LABORATORIES LIMITED; Takeda UK Ltd; Teva UK Limited; Theramex HQ UK; Thornton and Ross Ltd; WOCKHARDT UK LIMITED; Xiromed; ZENTIVA PHARMA UK LIMITED; medac Pharma LLP
- End date in notice
- 30 Apr 2029
- Value shown in notice
- £1,241,520,444Whole award value; not assigned to one supplier
- Official source
- Open the official Contracts Finder notice